AstraZeneca reported positive Phase III results for baxdrostat, an aldosterone synthase inhibitor targeting uncontrolled and treatment-resistant hypertension. The trial demonstrated significant reductions in systolic blood pressure and met secondary endpoints including response rates in resistant hypertension. Baxdrostat was generally well tolerated and showed a favorable safety profile with no major safety concerns during a one-year evaluation period. The successful trial validates AstraZeneca’s $1.8 billion acquisition of CinCor Pharma. The company plans to file for regulatory approval following detailed data presentations and aims to introduce a novel mechanism into a market that has seen limited innovation over two decades.